{"name":"Homology Medicines","slug":"homology","ticker":"FIXX","exchange":"NASDAQ","domain":"homologymedicines.com","description":"Homology Medicines is a gene therapy company focused on rare diseases. The company is developing a pipeline of gene therapies, including HMI-202 and HMI-203, for the treatment of mucopolysaccharidosis type IIIB (MPS III-B) and Hunter syndrome. Homology Medicines has a strong presence in the gene therapy market, with a focus on developing treatments for rare genetic disorders.","hq":"Bedford, MA","founded":0,"employees":"","ceo":"Albert Seymour","sector":"Gene Therapy / Rare Disease","status":"active","statusNote":"","leadDrug":"","leadIndication":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"$75M","metrics":{"revenue":5000000,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2034-06-01","label":"HMI-202 patent cliff ($0.0B at risk)","drug":"HMI-202","type":"patent_expiry","sentiment":"negative"},{"date":"2035-06-01","label":"HMI-203 patent cliff ($0.0B at risk)","drug":"HMI-203","type":"patent_expiry","sentiment":"negative"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[{"date":"2024-02-28","type":"earnings","headline":"Homology Medicines Reports Fourth Quarter and Full Year 2023 Financial Results","summary":"Homology Medicines reported its fourth quarter and full year 2023 financial results, with a net loss of $44.6 million for the year.","drugName":"","sentiment":"neutral"},{"date":"2023-11-14","type":"deal","headline":"Homology Medicines Announces Collaboration with the National Institutes of Health (NIH) to Develop Gene Therapies for Rare Genetic Disorders","summary":"Homology Medicines announced a collaboration with the NIH to develop gene therapies for rare genetic disorders, including MPS III-B and Hunter syndrome.","drugName":"","sentiment":"positive"},{"date":"2023-08-01","type":"trial","headline":"Homology Medicines Announces Positive Interim Results from Phase 1/2 Clinical Trial of HMI-202","summary":"Homology Medicines announced positive interim results from its Phase 1/2 clinical trial of HMI-202, a gene therapy for MPS III-B.","drugName":"","sentiment":"positive"}],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiU0FVX3lxTE5KUWY0RF9ybXppQlVYbzdXWVUzNHFlX2h4aVBLN0kzRV9nRFA4RkJCbXRYbmVqalpYOHJHVGtXOGl5ckw2UkVUSXZhNlpaRFJjcXpB?oc=5","date":"2025-04-25","type":"pipeline","source":"Stock Titan","summary":"FIXX Stock Price, News & Analysis - Stock Titan","headline":"FIXX Stock Price, News & Analysis","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilAFBVV95cUxNWU5WNWVCRG1DRjFYWGZRZWFYaXppZFVBZnJtTEVnb1M2RG9WM29OV0laR2Rac2FjRmItYVBwWG5MczFKam84RGNZZXJlbVlEZnNJVThjd1M5NFB3amdBQkMyZGtzbUdJUlYxVmc3UnJobTV1R1d2dnFKNm9mSk1lRTROb1dNY1dPdnRmWW8wLWtYTE9u?oc=5","date":"2024-01-02","type":"pipeline","source":"The Business Journals","summary":"The definitive Boston biotech layoff tracker for 2023 - The Business Journals","headline":"The definitive Boston biotech layoff tracker for 2023","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMisgFBVV95cUxQTzM0TGRweHpzRGE0aWlES2lTLVBVdEFJRXFfUHpPZUFtcjBuOWpUN1RIblhQRno1SGNtcV9oRGhaUWd5UmRhbjZNWThEZVlQWHhvN3RkNHF4dEk5ZWJVUnhTSFRWNUdWSlEwV0lOczFScXA0ZGFJQTc4WXB2Nk9hbWdsMGZJTndsWVJhbGtMbVpsV2l6RWtpb3ZHbjFBVzBPa3FGMG5mblFESG8xZlM3dF93?oc=5","date":"2023-11-16","type":"earnings","source":"PR Newswire","summary":"Q32 Bio and Homology Medicines Announce Merger Agreement - PR Newswire","headline":"Q32 Bio and Homology Medicines Announce Merger Agreement","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikgFBVV95cUxPanJGWDdjLUpVd3FQYmpBQWsybmRtdUw0Z1FXeUowREctZ0FfeWZuQWlJclQ2enhhU3dOTm43SXEyYnNMU3pBLTBMbHk2bTNNbzRQekltdnY5RU9MM0JTZ0ZZbGNhNmdYVzF2ckZQYnJqMmgtS0VtU1hjbDR0dnlTMElyQVBRVDNud1RBb2FNRkhqdw?oc=5","date":"2023-11-16","type":"pipeline","source":"The Business Journals","summary":"Big Pharma-backed startup to go public by merging with gutted Homology - The Business Journals","headline":"Big Pharma-backed startup to go public by merging with gutted Homology","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimgFBVV95cUxOaTdfV1dWTnI5dXV5SF9jLVBCbF9aaHRIRnk2NTBEaHljM1M0TWJiZldscGRrNWF4eDJ2cHN6c1RFUHptbHI3bm9SMHJXbVM3WkhWQkpoLWUzbW91cDVMclhRR2txYlFaUWRNNjJQVzNYd3NyM3pBR0NZTHJnWXd4MFBkek9sMkpwNEVITjE3VzNYazNFenUxbUNR?oc=5","date":"2023-10-02","type":"earnings","source":"The Business Journals","summary":"Biotech layoffs 2023: In Q3, 19 Boston-area biotechs made cuts - The Business Journals","headline":"Biotech layoffs 2023: In Q3, 19 Boston-area biotechs made cuts","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirAFBVV95cUxQckUyVkdPRkxHSktDbk9DUU40dGE0bmh3VkhKanZaLWNXeWVkay1VVjBrV0hGdXkydndwNWtZU19hZVZNdGQ2ZU12Z1dfNjJWMi1UR2dSdzZRVjQ4ZnlVNjBDcFdOdmZvTTQwWHdSdnhOYmtmM0E0NDNldVdHZUYzN1ZOY0lFUGpDMmRwTmNydEs5SEk5MXpzUXdhaFNwbGZVUHRYUEpPLVdJbW01?oc=5","date":"2023-03-09","type":"pipeline","source":"citybiz","summary":"Homology Medicines Promotes Julie Jordan, M.D., to Chief Medical Officer - citybiz","headline":"Homology Medicines Promotes Julie Jordan, M.D., to Chief Medical Officer","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2022-03-10","type":"deal","source":"GlobeNewswire","summary":"Homology Medicines Announces Closing of Deal Leveraging its - GlobeNewswire","headline":"Homology Medicines Announces Closing of Deal Leveraging its","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi3AFBVV95cUxOeWt2SnVqbjRTZkhEUzY4SEZkTE5qVTBLMl92Y294c2k3RnNQdmJqek1UUlFOV3ZULURhbE1vQmVVRGFIM0dqWHdRX2h0U2lWV3F4SDctX3B0X3ZxanpSS2g2d2NSeXZVWF8yZXJNeXNoSTR1dkVYazFPck5mOE5yU0k2MXo4V2VhREl4TC1kYm5udExmcEpxOTdqYnVFQzVMaVF1SUZ0bEpfMnJZUU9fZWtWUXM5WWI3MWFnMkpIRERKVnBSdGtlVHZyOHowYk81OXpibF9YM3VXRFZE?oc=5","date":"2022-01-28","type":"deal","source":"Reuters","summary":"Britain's Oxford Biomedica enters into deal to expand viral vector offerings - Reuters","headline":"Britain's Oxford Biomedica enters into deal to expand viral vector offerings","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqgFBVV95cUxObnk0MWdnNXhfbG5CVE5wd3lkVUtFVmswamRwLWNMT3kxd3dXN19GODBTbDlBbzdCM2FicFVKQVczRnVvZTdSZDlZMHpHVEpDVXBGREhOMTAxVFNUZms1VWRxMkw3b2VxSFVkTWMtdDNHc0MwUFdpT09CV1JDOTRBVGtVZG5OWTlOdndBd3J5RllzYmhWMWIwYWUyVlBFcU9iQlFta21TYm1Ndw?oc=5","date":"2020-01-10","type":"pipeline","source":"The Business Journals","summary":"Cambridge startup raises $110M for re-doseable gene therapies - The Business Journals","headline":"Cambridge startup raises $110M for re-doseable gene therapies","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMibkFVX3lxTFBNZVd5OEE1RE0zY1RIcjQyX2ZUenRRcjJzS1d2TERFQkZ2dHNwOEFPTmZqcmhPVG5mSU9QcTdZd2JHTVVZMlNQY19MOGljY0VkNXUzU2N1dDZEamRDN1FRb1VSTlJDaWVIZHlUY21B?oc=5","date":"2019-03-08","type":"pipeline","source":"Nanalyze","summary":"Precision BioSciences Stock Offered in IPO - Nanalyze","headline":"Precision BioSciences Stock Offered in IPO","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMicEFVX3lxTFBVTUpvM0lWOURrRGxBLUtuMndxME51Umg0bVM1SUY5UVBJMDVGVldfRTRDc2dHQTE1NXk2RmpuY2lXbDUzb2Q2eWxacl9Qem03UnVYODJHN3RfeTdLaXNpdlItTVpRUk8tc0tHeHpIM1I?oc=5","date":"2018-09-28","type":"pipeline","source":"Business Insider","summary":"The market for biotech IPOs is red hot — here are the top 10 of 2018 - Business Insider","headline":"The market for biotech IPOs is red hot — here are the top 10 of 2018","sentiment":"neutral"}],"patents":[{"drugName":"HMI-202","drugSlug":"mucopolysaccharidosis-type-iiib-(mps-iii-b)","patentNumber":"","type":"Patent Cliff","expiryDate":"2034-06-01","territory":"US","annualRevenue":0},{"drugName":"HMI-203","drugSlug":"hunter-syndrome","patentNumber":"","type":"Patent Cliff","expiryDate":"2035-06-01","territory":"US","annualRevenue":0}],"drugCount":0,"phaseCounts":{},"enrichmentLevel":3,"visitCount":2,"keyCompetitors":["Sangamo Therapeutics","Editas Medicine","CRISPR Therapeutics"],"therapeuticFocus":["Gene Therapy","Rare Diseases"],"financials":null,"yahoo":null}